Drug
Denosumab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Group | Anti-RANKL mAb |
| Mechanism of Action | Anti-RANKL antibody |
| Half-life | 26 d |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No radiosensitization mechanism; bone-protective with modest immunomodulation (Ahern et al., Nature Reviews Clinical Oncology, 2018; Chang et al., Cancer Immunology Research, 2024). No mechanistic basis for increased in-field radiation adverse events; the relevant class caution (osteonecrosis of the jaw, hypocalcemia) is independent of radiosensitization.
Data on this page refer exclusively to patients treated with
Denosumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Anti-RANKL mAb group page.